Industries
Pharma & biologics
What changes this industry: bio-solutions with evidence, technologies, suppliers and open money.
Overview of the industry
Drugs and biologics and the work that gets them made and approved: antibodies, bispecific antibodies and antibody-drug conjugates, new-generation antibiotics against resistant infections, bacteriophage therapy, chemoenzymatic and biosynthetic synthesis of active ingredients, and AI-assisted drug design. The technologies also include the supporting layer of biologic scale-up and aseptic fill-finish, analytical and endotoxin testing, CMC regulatory consulting and clinical-trial logistics.
What it replaces 0
No graded substitution linked yet.
Technologies 40
| ADC linker chemistry The conjugation chemistry that turns an antibody into a payload delivery vehicle — cleavable linkers, site-specific coupling and high-potency payload … | Therapeutics & platforms |
| AI clinical-trial patient recruitment Machine-learning software that scans structured and unstructured electronic health records to identify patients meeting a clinical trial's eligibility criteria … | Digital & IT |
| AI drug design & AlphaFold applications AI-driven drug discovery — AlphaFold structure prediction, generative chemistry and physics-based virtual screening — compressing the target-to-candidate … | Therapeutics & platforms |
| Anti-AMR antibiotics Next-generation antimicrobial compounds and beta-lactamase-inhibitor combinations designed to overcome multi-drug-resistant bacterial infections — a field with … | Therapeutics & platforms |
| Antibody-drug conjugates (ADCs) A monoclonal antibody chemically linked to a highly potent cytotoxic payload, delivering chemotherapy-grade cell killing selectively to antigen-expressing tumor … | Therapeutics & platforms |
| Automated visual inspection Standalone machine-vision systems that inspect every filled vial, ampoule, syringe and cartridge for visible particulates, fill-level deviations, cosmetic glass … | Fill-finish & packaging |
| Bacteriophage therapy Naturally occurring or precision-engineered bacterial viruses that selectively lyse a target pathogen without disrupting the rest of the microbiome — a genuine … | Therapeutics & platforms |
| Biologics Biologics — monoclonal antibodies, ADCs, CAR-T and gene therapy — are the largest and fastest-growing drug class, built on a reproducible cell-line platform at … | Therapeutics & platforms |
| Biopharmaceuticals & biomedicines Large-molecule therapeutics manufactured via living cells to treat complex diseases like cancer, diabetes, and autoimmune disorders. | Therapeutics & platforms |
| Bioproduction CDMO/CMO (biologics/ATMP/mRNA) Contract development and manufacturing organizations providing specialized infrastructure for advanced biopharmaceuticals. | Therapeutics & platforms |
| Biospecimen logistics for clinical trials Temperature-controlled, chain-of-custody transport and storage of patient-derived samples between trial sites, central labs, and biorepositories. | Logistics & supply chain |
| Biosynthetic steroids (fermentation & biocatalytic API) Corticosteroid and reproductive-hormone APIs made by mycobacterial fermentation of phytosterol into AD/ADD/9-OHAD precursors, then biocatalytic and … | Therapeutics & platforms |
| Bispecific & multispecific antibodies Engineered antibodies that bind two (or more) antigens on one molecule — most powerfully a CD3 arm that recruits the patient's own T cells to a tumour cell — … | Therapeutics & platforms |
| Capillary electrophoresis for biopharma Capillary-based separation instruments — CE-SDS purity assays, imaged capillary isoelectric focusing (icIEF) for charge-variant analysis, CE-mass spectrometry, … | Analytics & PAT |
| Chemoenzymatic API synthesis (biocatalytic small-molecule manufacturing) Engineered-enzyme steps (transaminases, ketoreductases, lipases) substituted into small-molecule API routes to replace metal-catalysed or multi-step chemical … | Therapeutics & platforms |
| Clinical-trial insurance brokerage Specialist insurance brokers who structure and place subject-injury, professional-indemnity and product-liability coverage for a clinical trial program, … | Insurance & risk |
| CMC regulatory consulting (BLA/MAA) Specialized strategic advisory services guiding biopharma through the complex Chemistry, Manufacturing, and Controls (CMC) requirements to successfully file … | Regulatory & legal |
| Distributor compliance auditing (GDP) Third-party audit firms that inspect pharmaceutical, biologic and cosmetic distributors and wholesalers against Good Distribution Practice (GDP) and … | Regulatory & legal |
| Drug & vaccine development The end-to-end R&D pipeline that carries a drug or vaccine candidate from target identification through Phase I-IV clinical trials to regulatory approval — a … | Therapeutics & platforms |
| Endotoxin testing systems Cartridge-based readers, kinetic microplate assays and reagent systems that detect bacterial endotoxin in injectable drugs, biologics and medical devices — the … | Analytics & PAT |
| FemTech biotech & women's health Specialized biologic, diagnostic and live-biotherapeutic products for conditions that affect exclusively or disproportionately women — non-invasive … | Regenerative & personalized medicine |
| Fill-finish & aseptic biomanufacturing High-precision sterile filling of advanced biological drugs into final delivery formats using isolated robotic environments. | Therapeutics & platforms |
| Gowning & contamination control Disposable and reusable cleanroom garments, gloves, wipes and gowning-room procedures that control personnel-shed particle and microbial contamination in … | Cleanroom & facilities |
| Mass spectrometers for biopharma characterization High-resolution and tandem mass spectrometers — Orbitrap, time-of-flight and triple-quadrupole platforms — that characterize protein identity, … | Analytics & PAT |
| Medical-affairs platforms (CME, MSL) Software platforms and CRM systems purpose-built for pharma medical-affairs teams — continuing medical education content, medical science liaison (MSL) field … | Market access & commercial |
| Microbiome therapeutics (live biotherapeutic products) Live biotherapeutic products (LBPs) — standardized, GMP-manufactured microbial consortia approved as drugs for recurrent C. difficile, inflammatory bowel … | Therapeutics & platforms |
| Named-patient programs & compassionate use Regulated pre-approval access to investigational biopharmaceuticals for patients with serious or life-threatening disease and no satisfactory alternative — … | Market access & commercial |
| Pass-through chambers and airlocks HEPA-filtered pass boxes and interlocked airlock chambers that move materials between cleanroom classification zones without breaking containment — static and … | Cleanroom & facilities |
| Patient digital twins & in-silico trials Computational patient models and virtual trial simulations used to reduce, accelerate or de-risk clinical development — AI-generated synthetic control arms, … | Regenerative & personalized medicine |
| Process validation and qualification (CRO) CRO-delivered three-stage process validation and IQ/OQ/PQ qualification of biopharma equipment — media fills, cleaning validation, CSV and viral clearance under … | Therapeutics & platforms |
| PROTACs (targeted protein degradation) Bifunctional small molecules that recruit an E3 ubiquitin ligase to a disease protein, tagging it for proteasomal destruction — an event-driven, catalytic drug … | Therapeutics & platforms |
| Proteomics (mass-spec CRO) Mass-spectrometry proteomics as a contract research service — deep DIA proteome profiling, targeted MRM/PRM and affinity proteomics for biomarker discovery and … | Bioinformatics & omics |
| Psychedelic medicine & neuropsychiatric biologics Psychoactive-compound therapies (psilocybin, MDMA, 5-MeO-DMT) and next-generation non-hallucinogenic psychoplastogens that trigger rapid synaptogenesis via … | Therapeutics & platforms |
| Radiopharmaceuticals & theranostics Radioactive compounds that pair a tumor-targeting vector with a diagnostic or therapeutic isotope — 'see what you treat, treat what you see' — now commercial at … | Therapeutics & platforms |
| Recombinant human serum albumin (rHSA) Recombinant human serum albumin (rHSA) replaces plasma-derived HSA (pHSA) — constrained by donor blood supply and viral contamination risk since the 1940s — … | Specialty & fine chemicals |
| Scale-up centers for innovative biologic small-batch production Public-private manufacturing-innovation institutes that operate shared pilot- and demonstration-scale biomanufacturing facilities, letting a biologic developer … | Automation & robotics |
| Serialization, labeling & track-and-trace The vision inspection, 2D-Data-Matrix printing, aggregation and multi-enterprise network software that stamp a unique identity onto every saleable drug unit and … | Fill-finish & packaging |
| Spray-freeze drying Freezing a liquid feed into a frozen matrix and sublimating the ice under vacuum — continuous spray-freeze variants inside the wider freeze-dryer line set. The … | Fill-finish & packaging |
| Sterilizing-grade filters 0.2-micron-rated membrane filters, cartridges and syringe filters that remove bioburden from process fluids, buffers and final drug product before fill-finish — … | Consumables |
| Structural biology (cryo-EM CRO) Cryo-electron microscopy as a contract research service — atomic 3D structures of membrane proteins and drug targets for structure-based drug design, displacing … | Bioinformatics & omics |
Opportunities 4
| Tender | Czechia – Immunosuppressive agents – Imunosupresivum, monoklonální protilátka s obsahovou látkou … Fakultní nemocnice Ostrava, Fakultní nemocnice Olomouc, Fakultní nemocnice Hradec Králové | Oct 13, 2026 6 days |
| Tender | Czechia – Immunosuppressive agents – Selektivní Imunosupresiva - Eculizumab IV. Institut klinické a experimentální medicíny | Oct 20, 2026 13 days |
| Tender | Czechia – Immunosuppressive agents – Takrolimus 1x denně - LP ADVAGRAF Institut klinické a experimentální medicíny | Oct 20, 2026 13 days |
| Tender | Netherlands – Influenza vaccines – Trivalent Influenza Vaccines 2026 Rijksinstituut voor Volksgezondheid en Milieu (RIVM), RIVM | Oct 19, 2026 12 days |